The prognosis data showed that the progression free survival (PFS) (p=0.0053, Figure 2E) and recurrence free survival (RFS) (p=0.015, Figure 2F) were shorter in HCC patients with higher MAP3K14 expression, while patients with lower MAP3K14 expression had better survival outcomes. Here, MAP3K14 is linked to hepatocellular carcinoma.